Compare ACADIA Pharmaceuticals Inc. (ACAD) vs InMode Ltd (INMD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs InMode Ltd — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while InMode Ltd trades at $14.46 (market cap $835.77M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 5.4× InMode Ltd's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, InMode Ltd nearer its low. Which is the better fit depends on your goals.
| ACAD | INMD | |
|---|---|---|
Market Cap | $4.49B | $835.77M |
Sector | Health | Technology |
52-Week High | $28.06 | $16.62 |
52-Week Low | $20.06 | $12.76 |
Enterprise Value | $3.69B | $303.44M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
INMD trades at $14.60, down 1.35% on the day, with mixed technical signals showing bullish moving averages but neutral oscillators. The company maintains strong profitability with 77.84% gross margins and 23.27% net income margins, though Q1 2026 earnings missed expectations. Recent news includes an unsolicited buyout proposal at $16.20 per share and multiple securities fraud investigations announced in early July 2026.
The stock appears undervalued with a P/E of 10.81 and EV/EBITDA of 3.81, but faces near-term headwinds from legal investigations and earnings volatility. Analyst consensus sits at Hold with a $16.50 price target, representing 13% upside potential from current levels, though the ongoing legal scrutiny creates uncertainty for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About InMode Ltd
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →
